among
approxim
adenovirus
chimpanze
bonobo
studi
recent
pan
adenoviru
type
isol
bonobo
pan
paniscu
one
best
profil
vaccin
vector
combin
potent
transgen
immunogen
minim
preexist
immun
human
popul
studi
insert
replic
defect
transgen
express
fusion
protein
conserv
influenza
antigen
nucleoprotein
np
matrix
studi
antibodi
cell
respons
well
protect
challeng
infect
mous
model
singl
intranas
administr
vaccin
induc
strong
antibodi
cell
respons
protect
high
dose
lethal
influenza
viru
challeng
thu
promis
candid
vector
vaccin
includ
univers
influenza
vaccin
influenza
continu
pose
global
health
problem
highlight
swine
influenza
pandem
sporad
human
infect
avian
influenza
virus
antigen
chang
influenza
viru
primarili
surfac
antigen
hemagglutinin
ha
neuraminidas
na
refer
antigen
shift
subtyp
chang
reassort
antigen
drift
mutat
variabl
among
influenza
virus
hinder
vaccin
effort
current
annual
surveil
necessari
identifi
circul
viral
strain
use
vaccin
product
new
vaccin
often
requir
take
month
becom
avail
thu
new
approach
need
contrast
socal
univers
vaccin
target
rel
conserv
compon
influenza
viru
provid
protect
regardless
strain
subtyp
viru
may
provid
altern
use
tradit
vaccin
immun
conserv
antigen
would
necessarili
prevent
infect
complet
might
decreas
sever
diseas
speed
viral
clearanc
reduc
morbid
mortal
initi
stage
outbreak
strainmatch
vaccin
becam
avail
furthermor
vaccin
base
cell
immun
could
use
combin
season
vaccin
improv
efficaci
especi
elderli
high
risk
sever
diseas
show
reduc
respons
current
flu
vaccin
peptid
scan
cell
respons
healthi
human
individu
shown
matrix
nucleoprotein
np
among
promin
target
cell
crossrecognit
interest
vaccin
candid
sequenc
homolog
np
conserv
among
influenza
isol
murin
human
cytotox
lymphocyt
induc
np
one
viru
strain
shown
crossreact
np
differ
influenza
strain
strong
immun
respons
np
mice
contribut
protect
challeng
via
cell
well
contribut
cell
antibodi
influenza
matrix
gene
encod
two
highli
conserv
protein
ion
channel
protein
capsid
protein
major
protect
antigen
mous
well
recogn
mous
cell
long
known
recogn
human
cell
thu
potenti
contribut
vaccin
protect
may
underestim
mous
studi
epitop
provid
target
wide
share
among
influenza
virus
identifi
multipl
viral
protein
highli
immunogen
present
classic
vaccin
potent
immun
achiev
use
recombin
vector
express
influenza
antigen
focu
immun
target
recombin
adenoviru
vector
especi
effect
elicit
strong
cell
respons
transgen
product
recombin
adenoviru
vector
express
np
np
protect
mice
rang
influenza
viru
challeng
includ
highli
pathogen
avian
strain
potenti
interfer
prior
immun
human
adenovirus
suggest
barrier
issu
circumv
use
vector
base
anim
adenovirus
chimpanze
adenovirus
shown
use
vaccin
vector
varieti
anim
studi
preval
neutral
antibodi
chimpanze
adenovirus
low
human
popul
equal
immunogen
studi
use
simian
adenoviru
isol
bonobo
pan
paniscu
novel
adenoviru
strain
identifi
studi
adenovirus
isol
chimpanze
bonobo
order
increas
avail
repertoir
vector
larg
scale
screen
experi
among
potent
immunogen
mice
also
among
least
frequent
recogn
neutral
antibodi
human
sera
gener
replic
incompet
vector
delet
region
express
fusion
protein
np
antigen
influenza
chosen
target
broad
crossreact
cell
immun
human
vaccin
test
induct
antibodi
cell
respons
system
mucos
compart
mice
well
protect
lethal
influenza
viru
challeng
demonstr
express
conserv
influenza
viru
antigen
provid
highli
effect
protect
singl
intranas
administr
thu
show
consider
promis
vaccin
candid
anim
protocol
procedur
approv
institut
anim
care
use
committe
center
biolog
evalu
research
protocol
conduct
spf
anim
facil
accredit
associ
assess
accredit
laboratori
anim
care
intern
experi
perform
accord
institut
guidelin
influenza
challeng
studi
anim
lost
initi
bodi
weight
human
euthan
avoid
suffer
highli
virul
mouseadapt
viru
afort
afm
previous
describ
kindli
provid
earl
brown
univers
ottawa
canada
prepar
pool
homogen
lung
balbc
mice
infect
viru
intranas
rout
day
earlier
pan
adenoviru
type
isol
stool
specimen
collect
bonobo
pan
paniscu
isol
amplifi
viru
genom
clone
plasmid
vector
fulli
sequenc
shown
phylogenet
tree
base
hexon
sequenc
member
adenoviru
speci
c
close
relat
speci
c
human
chimpanze
adenovirus
alreadi
use
preclin
clinic
trial
human
vector
construct
homolog
recombin
e
coli
strain
cotransform
purifi
viral
dna
shuttl
vector
homolog
recombin
pix
gene
right
itr
dna
sequenc
present
end
linear
shuttl
viral
genom
dna
allow
insert
plasmid
vector
simultan
replac
region
human
cytomegaloviru
hcmv
promoterdriven
egfp
express
cassett
contain
bovin
growth
hormon
polyadenyl
signal
bgh
polya
gener
region
nucleotid
delet
sever
clone
homolog
recombin
step
gener
backbon
propag
hek
cell
express
cassett
contain
consensu
sequenc
np
plu
human
cytomegaloviru
promot
bovin
growth
hormon
polyadenyl
signal
construct
influenza
express
cassett
contain
consensu
sequenc
np
influenza
np
sequenc
obtain
ncbi
influenza
viru
resourc
databas
http
wwwncbinlmnih
govgenomesflufluhtml
protein
sequenc
chosen
among
differ
subtyp
strain
isol
caus
infect
human
worldwid
np
consensu
sequenc
deriv
align
nonident
sequenc
sequenc
use
muscl
version
appli
major
rule
np
sequenc
use
vaccin
lack
nuclear
local
signal
resid
aa
tkr
mutat
aaa
result
increas
cytoplasm
accumul
consensu
sequenc
similarli
deriv
align
nonident
sequenc
sequenc
np
sequenc
space
flexibl
linker
gggsggg
result
sequenc
codonoptim
express
eukaryot
cell
diagram
insert
full
sequenc
given
figur
express
cassett
insert
backbon
via
homolog
recombin
ecoli
sequenc
hiv
gag
protein
respiratori
syncyti
viru
rsv
fusion
protein
f
protein
nucleoprotein
n
transcript
factor
insert
construct
use
specif
control
express
cassett
insert
pneb
shuttl
vector
transfer
snabi
linear
plasmid
homolog
recombin
e
coli
exploit
homolog
hcmv
promot
bgh
polya
sequenc
vector
produc
procel
cell
deriv
hek
cell
line
origin
bank
univers
leiden
obtain
frank
graham
macmast
univers
hamilton
canada
adapt
suitabl
manufactur
incorpor
plasmid
carri
tet
repressor
express
cassett
gene
protocol
gener
procel
cell
line
follow
essenti
publish
matthew
et
al
briefli
hek
cell
transfect
express
vector
contain
cassett
encod
tet
repressor
control
human
phosphoglycer
pgk
promot
gene
singl
clone
select
grow
transfect
cell
presenc
mg
ml
cultur
medium
singl
clone
amplifi
test
tet
repressor
express
western
blot
analysi
stabil
tet
repressor
express
select
clone
test
passag
vector
grown
cell
purifi
cesium
chlorid
gradient
store
buffer
viral
particl
vp
measur
adenoviru
stock
made
measur
absorb
nm
describ
peptid
np
tyqrtralv
sar
hagsndniallvq
synthes
cber
core
facil
mhci
restrict
peptid
adenoviru
dnabind
protein
dbp
falsnaedl
present
recombin
protein
strain
purchas
genscript
piscataway
nj
recombin
nucleoprotein
rnp
strain
purchas
imgenex
san
diego
ca
hela
cell
infect
indic
multipl
infect
moi
extract
prepar
hour
infect
use
ten
buffer
mm
tri
ph
mm
nacl
mm
edta
ph
triton
proteas
inhibitor
nuclei
cell
debri
spun
centrifug
g
minut
glycerol
ad
supernat
store
express
assess
western
blot
mous
hyperimmun
serum
rais
antigen
mice
euthan
bronchoalveolar
lavag
bal
fluid
lung
cell
obtain
price
et
al
briefli
bal
fluid
lung
flush
ml
phosphatebuff
salin
pb
lung
cell
isol
gradient
centrifug
minc
collagenasedigest
lung
tissu
splenocyt
deplet
erythrocyt
treatment
ack
lysi
buffer
sera
blood
collect
abdomin
vena
cava
isol
use
bd
microtain
franklin
lake
nj
decompl
heattreat
minut
cell
elispot
assay
perform
describ
previous
briefli
antiinterferon
ifn
c
mab
bd
pharmingen
san
jose
ca
use
coat
elispot
plate
millipor
billerica
splenocyt
lung
cell
ad
well
concentr
cellswel
necessari
also
cellswel
bring
result
countabl
rang
ct
medium
peptid
ad
final
concentr
mgml
plate
incub
hr
co
bound
ifnc
detect
biotinyl
mab
bd
pharmingen
follow
incub
alkalin
phosphataselabel
streptavidin
kpl
gaithersburg
md
ml
tetrazolium
use
develop
substrat
kpl
spot
count
elispot
reader
zeiss
thornwood
ny
antibodi
level
serum
bal
measur
enzymelink
immunosorb
assay
elisa
benton
et
al
specif
nunc
plate
coat
overnight
mgml
rnp
mgml
pb
block
next
individu
mous
sera
bal
ad
plate
bound
antibodi
detect
use
humanadsorb
alkalin
phosphataseconjug
goat
antimous
igg
iga
southern
biotechnolog
associ
birmingham
al
follow
substrat
pnitrophenyl
phosphat
sigma
od
measur
nm
neutral
antibodi
titer
assay
previous
describ
modif
briefli
cell
per
well
seed
well
plate
cultur
day
adenovir
vector
express
secret
alkalin
phosphatas
seap
incub
hour
alon
serial
dilut
serum
ad
confluent
cell
incub
hour
supernat
remov
replac
fc
dmem
seap
express
measur
hour
later
use
chemiluminesc
substrat
cspd
phosphalighttm
kit
tropix
cat
appli
biosystem
bedford
without
heat
inactiv
light
emiss
rel
light
unit
rlu
monitor
minut
addit
cspd
substrat
use
envis
multilabel
reader
perkin
elmer
waltham
surviv
data
vaccin
group
vs
control
compar
logrank
analysi
bonferroni
method
use
prism
graphpad
softwar
inc
la
jolla
ca
construct
design
use
two
conserv
influenza
antigen
import
human
immun
np
analyz
level
transgen
express
hela
cell
infect
variou
moi
triton
extract
prepar
western
blot
analysi
extract
perform
use
mous
hyperimmun
serum
rais
antigen
kd
major
band
seen
consist
fusion
protein
fig
kd
band
also
detect
western
blot
develop
monoclon
antibodi
np
data
shown
immun
respons
compar
im
rout
intranas
immun
especi
effici
induct
local
immun
respiratori
tract
includ
recruit
memori
cell
airway
given
vaccin
induc
greater
mucos
immun
respons
intramuscular
im
immun
weaker
system
respons
pilot
studi
includ
rout
immun
order
character
respons
induc
new
vector
antibodi
respons
sera
individu
mice
week
immun
test
antibodi
np
shown
figur
equival
igg
respons
np
detect
serum
respons
given
either
im
dose
viral
particl
vp
serum
antibodi
respons
reduc
anim
immun
lower
dose
vp
bal
antinp
igg
antibodi
induc
im
immun
fig
induc
littl
iga
bal
fig
reagent
control
provid
bal
immun
mice
system
known
previou
studi
induc
iga
show
assay
could
detect
iga
antibodi
present
cell
respons
function
cell
respons
vaccin
measur
ifnc
elispot
figur
show
respons
spleen
lung
np
peptid
immunodomin
mhc
epitop
cell
balbc
mice
immun
im
produc
much
higher
frequenc
npspecif
cell
spleen
immun
revers
true
lung
result
show
anatom
local
immun
respons
effici
prime
cell
respiratori
tract
consist
previou
studi
respons
np
seen
mice
immun
construct
contain
irrelev
transgen
hiv
gag
none
mice
respond
sar
control
peptid
pilot
experi
show
protect
challeng
four
week
postvaccin
vp
given
data
shown
thu
vector
promis
pursu
detail
studi
given
superior
administr
induc
cell
respons
lung
explor
immun
respons
vaccin
mucos
rout
use
control
irrelev
rsv
insert
mice
immun
dose
vp
per
mous
antibodi
respons
serum
bal
analyz
igg
iga
antibodi
np
figur
show
result
igg
antibodi
np
serum
bal
highest
vaccin
dose
vp
per
mous
strong
igg
respons
seen
vaccin
dose
given
mice
reduc
vp
per
mous
antibodi
respons
greatli
reduc
serum
absent
bal
iga
antibodi
respons
undetect
serum
margin
bal
fig
figur
reagent
control
provid
bal
immun
mice
show
assay
could
detect
iga
antibodi
present
antibodi
respons
compon
includ
iga
data
shown
igg
respons
substanti
serum
fig
cell
respons
cell
respons
measur
ifnc
elispot
dose
vp
induc
strong
cell
respons
lung
domin
np
epitop
control
induc
modest
respons
adenoviru
peptid
dbp
fig
hundredfold
lower
dose
induc
littl
respons
either
np
dbp
immun
protect
challeng
infect
one
month
immun
mice
challeng
ld
tcid
afm
rel
high
dose
highli
pathogen
viru
shown
figur
dose
vp
less
protect
dose
vp
provid
consider
protect
stringent
challeng
mice
surviv
display
much
less
morbid
control
shown
weight
loss
crossneutr
human
antibodi
close
relat
virus
belong
adenoviru
group
c
one
aspect
whether
vector
like
block
preexist
immun
test
neutral
viru
human
sera
select
particularli
high
neutral
antibodi
titer
shown
tabl
mani
hightit
sera
neutral
activ
human
sera
high
neutral
titer
rang
low
neutral
titer
effort
develop
univers
influenza
vaccin
variou
platform
immun
conserv
antigen
studi
replic
incompet
adenoviru
vector
promis
sinc
strong
induct
innat
immun
respons
provid
builtin
adjuv
antigenspecif
b
cell
respons
induc
sustain
long
time
anim
adenovirus
potenti
advantag
human
prior
exposur
reason
chimpanze
adenovirus
recent
begun
explor
use
vaccin
vector
human
show
good
safeti
excel
immunogen
furthermor
test
four
chimpanze
adenoviru
vector
prior
immun
gfpexpress
construct
block
subsequ
respons
transgen
product
homolog
vector
crossblock
minim
studi
test
new
vector
base
bonobo
viru
bonobo
viru
belong
adenoviru
speci
c
speci
b
exampl
shown
studi
less
immunogen
speci
c
sinc
close
relat
may
share
certain
structur
featur
provid
power
intern
adjuv
effect
thu
higher
immunogen
despit
structur
similar
human
sera
contain
high
neutral
titer
show
margin
neutral
capac
moreov
screen
studi
shown
potent
vector
mice
primat
show
singl
administr
influenza
vaccin
given
provid
highli
effect
protect
lethal
challeng
mouseadapt
afm
greatli
reduc
morbid
mortal
compar
control
protect
compar
previous
publish
studi
express
conserv
influenza
viru
antigen
challeng
viru
dose
vaccin
induc
antibodi
cell
respons
np
mention
earlier
cell
respons
np
wellknown
contribut
protect
recent
studi
report
antibodi
np
also
contribut
protect
fusion
protein
np
express
vaccin
advantag
includ
anoth
major
target
human
immun
use
multipl
target
antigen
may
invok
differ
immun
mechan
reduc
likelihood
gener
escap
mutant
provid
larger
rang
epitop
may
suitabl
differ
mhc
type
although
expect
play
much
role
protect
mice
promin
target
cell
immun
human
might
contribut
perform
vaccin
human
result
present
support
use
vector
vaccin
candid
highli
effect
induc
cell
antibodi
immun
time
advantag
neutral
human
sera
thu
use
express
conserv
influenza
viru
antigen
promis
univers
influenza
vaccin
candid
tabl
sera
healthi
human
individu
differ
geograph
area
europ
unit
state
screen
previous
neutral
activ
select
sera
high
neutral
activ
titer
test
neutral
describ
materi
method
use
vector
express
secret
alkalin
phosphatas
seap
report
gene
arbitrari
sampl
number
result
two
test
ethic
statement
volunt
gave
written
inform
consent
particip
studi
conduct
accord
principl
declar
helsinki
accord
good
clinic
practic
doc
